A major highlight from @NateraGenetics at @ASCO #GI25: New trial showing how Signatera can enhance disease management for colorectal cancer patients with personalized treatment. 

This could be a game-changer in how we manage and treat colorectal cancer— one of the deadliest cancers in the world.
#GI25